BNP Paribas Financial Markets Acquires 37,866 Shares of Agenus Inc. (NASDAQ:AGEN)

BNP Paribas Financial Markets raised its holdings in Agenus Inc. (NASDAQ:AGEN) by 2,271.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 39,533 shares of the biotechnology company’s stock after acquiring an additional 37,866 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.18% of Agenus worth $217,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Ovata Capital Management Ltd acquired a new stake in Agenus in the second quarter valued at $670,000. Federated Hermes Inc. acquired a new stake in Agenus during the 2nd quarter valued at approximately $1,921,000. Blair William & Co. IL bought a new position in Agenus during the 2nd quarter worth approximately $441,000. Point72 DIFC Ltd acquired a new position in shares of Agenus in the 2nd quarter worth approximately $51,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Agenus during the second quarter worth $614,000. Institutional investors own 61.46% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Agenus Stock Down 7.2 %

Shares of AGEN stock opened at $2.83 on Tuesday. The firm has a 50 day moving average of $3.77 and a 200-day moving average of $7.31. The company has a market cap of $66.39 million, a price-to-earnings ratio of -0.25 and a beta of 1.24. Agenus Inc. has a 52 week low of $2.50 and a 52 week high of $19.69.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.